Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 543 participants.
Also called NCT02762578
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 543 participants
- Sponsor
- Registry
-
NCT02762578 -
2011-000085-36
-
- Other papers using this trial's data
- Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02762578. Randomized; no masking; primary purpose treatment. Start 2016-05-03 (actual); primary completion 2017-05-19 (actual). Results posted on 2018-12-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes
- Acronym
- BOOST
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- biphasic insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02762578- Content hash
52b2ee93dfa4152827f239e746f46ae371d23922e6ef66195f0b6472c86d860d